Company intelligence / Profile preview

RosVivo Therapeutics

Reno, Nevada, United States

Ownership: Private
Development stage: Other

Overview

Pre-clinical stage biotech developing miRNA-based therapies for metabolic diseases including diabetes; RSVI-301 shows efficacy in restoring beta cell function and reducing insulin resistance in animal models with fewer side effects than GLP-1 agonists.

Therapeutic areas: GastroenterologyEndocrinologyInfectious Diseases
Modalities: miRNA
Industry: Biotech

Drug pipeline

3 assets

RSVI-305

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly and Company

Beyond the preview

Go deeper on RosVivo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RosVivo Therapeutics.

Explore the full profile